Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. S&P 500 (SPY)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.69B | 4.22B | 3.20B | 2.96B | 2.61B | Gross Profit |
| 2.66B | 2.36B | 1.84B | 1.72B | 1.54B | EBIT |
| 1.32B | 1.13B | 903.68M | 809.66M | 579.26M | EBITDA |
| 1.53B | 1.35B | 1.18B | 1.10B | 922.89M | Net Income Common Stockholders |
| 1.02B | 897.56M | 474.50M | 474.50M | 404.59M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 238.36M | 227.89M | 295.28M | 463.16M | 147.13M | Total Assets |
| 6.87B | 6.75B | 4.73B | 4.59B | 4.11B | Total Debt |
| 873.93M | 1.58B | 793.72M | 1.30B | 1.27B | Net Debt |
| 635.57M | 1.35B | 498.44M | 836.11M | 1.12B | Total Liabilities |
| 2.01B | 2.62B | 1.84B | 2.09B | 2.04B | Stockholders Equity |
| 4.86B | 4.13B | 2.89B | 2.50B | 2.07B |
| Cash Flow | Free Cash Flow | |||
| 1.29B | 559.30M | 619.89M | 696.32M | 381.71M | Operating Cash Flow |
| 1.40B | 693.30M | 736.72M | 802.25M | 459.05M | Investing Cash Flow |
| -269.78M | -1.16B | -158.46M | -179.86M | -1.08B | Financing Cash Flow |
| -1.12B | 422.87M | -764.63M | -764.63M | 580.64M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
ResMed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for April 2025, with a reduction of 9,500,350 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock on the NYSE. Additionally, there has been an increase in other securities due to stock options, restricted stock units, employee stock purchase plans, and share repurchases on the NYSE, reflecting the company’s ongoing financial and operational adjustments.
ResMed Inc. has filed its quarterly report for the period ending March 31, 2025, indicating compliance with all necessary regulatory requirements. The report includes detailed financial statements and management’s discussion on the company’s financial condition and operational results. This filing underscores ResMed’s commitment to transparency and regulatory adherence, which is crucial for maintaining investor confidence and supporting its market position.
ResMed Inc has announced a new dividend distribution for its CHESS Depositary Interests (CDIs) at a ratio of 10 CDIs per ordinary share. The dividend amount is set at USD 0.053 per CDI, with an ex-date of May 7, 2025, a record date of May 8, 2025, and a payment date of June 12, 2025. This announcement reflects the company’s ongoing commitment to providing value to its shareholders and may impact its market positioning by reinforcing investor confidence in its financial health and operational stability.
Resmed Inc. reported strong financial results for the third quarter of fiscal year 2025, with an 8% increase in revenue and a 14% rise in operating profit compared to the previous year. The company’s performance was driven by robust customer demand for its sleep devices, masks portfolio, and Residential Care Software business, resulting in a 9% revenue growth on a constant currency basis. Resmed’s strategic focus on expanding its market-leading value proposition in connected digital health contributed to a 140 basis point improvement in gross margin and double-digit earnings per share growth. The company’s commitment to increasing patient flow and awareness among healthcare providers underscores its ongoing efforts to enhance its industry positioning and stakeholder value.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 1,000 shares of common stock. The aggregate market value of these shares is approximately $215,580, and the sale is scheduled for April 8, 2025, on the NYSE. This move follows previous sales by Sandercock in the past three months, reflecting a strategic decision that may impact the company’s stock liquidity and investor perception.
ResMed Inc has reported a change in beneficial ownership as Peter C. Farrell, the Chairman emeritus, disposed of 2,000 shares of ResMed common stock on April 2, 2025, under a pre-established Rule 10b5-1 plan. This transaction reflects ongoing management of personal holdings by company executives, which may influence investor perceptions and the company’s stock market performance.
ResMed Inc has announced a decrease in the total number of CHESS Depositary Interests (CDIs) issued over quoted securities, with a net reduction of 2,878,870 CDIs from the previous month. This change is attributed to net transfers between CDIs and common stock as quoted on the NYSE. Additionally, there has been an increase in the total number of securities over which CDIs have not been issued, due to transfers, new share issues related to stock options, and share repurchases on the NYSE. These adjustments reflect the company’s ongoing management of its securities and stock plans.
ResMed Inc has reported a transaction involving its Global General Counsel, Michael J. Rider, who disposed of 64 shares of the company’s common stock at a price of $222.86 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan. The impact of this transaction on the company’s operations or market positioning is not explicitly detailed in the release, but such transactions are typically routine and part of personal financial management by executives.
ResMed Inc. has announced the proposed sale of 2,000 common shares by Peter C. Farrell, a director of the company, under Rule 144 of the Securities Act of 1933. The shares, acquired through a stock option exercise in 2013, are set to be sold on the NYSE with an aggregate market value of $444,600. This move is part of a series of sales by Farrell, who has sold similar amounts of shares in the past three months, potentially impacting the company’s stock dynamics and stakeholder interests.
Resmed announced it will release its third-quarter fiscal year 2025 financial and operational results on April 23, 2025, after the New York Stock Exchange closes. The company will host a webcast to discuss these results, which may include additional forward-looking and material information, potentially impacting stakeholders and providing insights into Resmed’s operational and market positioning.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, executed a transaction involving the sale of 1,000 shares of ResMed common stock at a price of $230.36 per share on March 10, 2025. This transaction was conducted under a pre-established Rule 10b5-1 plan, which provides certain legal protections for insider trading. The sale leaves Sandercock with a beneficial ownership of 90,864 shares, highlighting a strategic move within the company’s executive management.
ResMed Inc.’s Chief Commercial Officer, Kaushik Ghoshal, reported changes in beneficial ownership of the company’s common stock through transactions executed under a Rule 10b5-1 plan. These transactions involved both acquisitions and dispositions of shares, reflecting strategic financial management by the executive. The transactions may have implications for the company’s stock performance and stakeholder interests, as they indicate executive confidence in the company’s market position and future prospects.
Resmed Inc has filed a Form 144 notice indicating the proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing details the sale of 9,745 common shares with an aggregate market value of approximately $2.33 million, to be executed on the NYSE. The transaction involves shares acquired through options granted in previous years, with the sale potentially impacting the company’s stock liquidity and market perception.
ResMed Inc. has reported a change in beneficial ownership as per a Form 4 filing with the SEC, indicating that CEO Michael J. Farrell executed transactions involving the acquisition and disposal of common stock under a pre-established Rule 10b5-1 plan. This transaction reflects the company’s ongoing adherence to regulatory compliance and may impact stakeholders’ perception of executive confidence in the company’s future performance.
ResMed Inc has filed a notice for the proposed sale of securities under Rule 144, with Brett Sandercock, an officer of the company, planning to sell 1,000 common shares. The transaction, scheduled for March 10, 2025, follows previous sales by Sandercock in January and February 2025, indicating a strategic move in managing personal holdings without any adverse information affecting the company’s operations.
Resmed Inc has filed a notice for the proposed sale of securities under Rule 144, with Michael J. Farrell, an officer and director of the company, planning to sell 8,009 common shares. The aggregate market value of these shares is approximately $1.8 million, and the sale is scheduled for March 7, 2025. This transaction is part of a planned trading strategy, and the company has ensured that no material adverse information is undisclosed, maintaining transparency with stakeholders.
ResMed Inc. has announced a proposed sale of securities under Rule 144, with Director Peter C. Farrell planning to sell 2,000 common shares. The sale, facilitated by Merrill Lynch, is part of a series of transactions by Farrell, who has previously sold shares in December 2024 and January 2025, indicating ongoing divestment activities. The aggregate market value of the shares to be sold is $500,000, reflecting a strategic financial decision that may impact stakeholder perceptions and the company’s market dynamics.
ResMed Inc. has reported changes in beneficial ownership as per a recent transaction conducted under a Rule 10b5-1 plan. The transactions involved the acquisition and disposal of ResMed common stock by Kaushik Ghoshal, the Chief Commercial Officer of the SaaS business, reflecting strategic financial management within the company.
ResMed Inc. has reported a change in beneficial ownership, with Michael J. Rider, the Global General Counsel, disposing of 64 shares of ResMed common stock at a price of $234.10 per share. This transaction, conducted under a Rule 10b5-1 plan, reflects the company’s ongoing compliance with regulatory requirements and may have implications for its stock market performance and investor relations.
ResMed Inc has announced a decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for February 2025, with a net reduction of 694,860 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock as quoted on the NYSE. Additionally, there was a decrease in the total number of securities over which CDIs have not been issued, due to transfers, new share issues related to stock options and employee plans, and share repurchases on the NYSE. These adjustments reflect ResMed’s ongoing management of its securities and share structure, potentially impacting its market positioning and stakeholder interests.
ResMed Inc has filed a Form 144 notice for the proposed sale of securities, indicating that an officer of the company, Kaushik Ghoshal, plans to sell 9,113 shares of common stock with an aggregate market value of approximately $2,145,408.15. The sale is scheduled for March 3, 2025, on the NYSE, and the shares were acquired through options granted in 2019 and 2020. This transaction reflects a routine financial move by company insiders and is not expected to impact the company’s operations or market positioning significantly.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Michael J. Rider, an officer of the company, plans to sell 64 shares of common stock. The sale is part of a restricted stock vesting transaction, with the shares acquired as compensation. This filing suggests ongoing insider transactions, which may influence investor perceptions of the company’s stock value and market performance.
ResMed Inc has updated the foreign exchange rate for its upcoming dividend distribution to CDI holders on the Australian Securities Exchange. The exchange rate is set at 0.6318 U.S. dollars per Australian dollar, with a dividend payment of 0.0839 Australian dollars per CDI. The announcement highlights that the default U.S. withholding tax on these dividends is 30%, but it can be reduced to 15% under the U.S.-Australia tax treaty if CDI holders submit the appropriate tax forms.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, executed a transaction under a Rule 10b5-1 plan, selling 1,000 shares of common stock at $238.98 per share. This planned transaction, which reflects strategic financial management, may impact stakeholders’ perceptions of the company’s financial strategy and market approach.
ResMed Inc.’s CEO, Michael J. Farrell, executed stock transactions under a pre-established Rule 10b5-1 plan, acquiring and disposing of shares. These transactions, involving common stock and stock options, showcase the company’s executive financial management and strategic planning, potentially influencing ResMed’s market perception and stakeholder interests.
ResMed Inc has filed a notice regarding the proposed sale of securities under Rule 144, indicating that Michael J. Farrell, an officer and director, plans to sell 8,009 common shares valued at approximately $1,896,307.29. This sale, along with previous transactions, highlights insider trading activities but assures that no adverse, undisclosed information about the company’s operations has influenced these decisions.